Latest Vaccines News: Spikevax Submissions, Oral COVID-19 Trials, MenQuadfi for Infants & More 🚀💉🧬
In this week’s edition of Vaccine Research Updates, we’re bringing you the most impactful developments in vaccine science and global immunization. From next-gen COVID-19 vaccines to expanded pediatric approvals and precision cancer immunotherapies—here’s what’s shaping the future of public health:
💉 Moderna submits its Spikevax 2025–2026 COVID-19 formulation to the FDA—targeting the LP.8.1 variant and aligning with the latest monovalent JN.1 guidance.
💊 Vaxart kicks off a 10,000-participant Phase 2b trial for its oral COVID-19 pill—backed by $460.7M in U.S. government funding, showing strong early safety signals.
🧒 MenQuadfi gains FDA approval for use in infants as young as six weeks—offering broad protection against meningococcal serogroups A, C, W, and Y.
🌍 Pfizer and BioNTech file an EMA application for their mRNA COVID-19 vaccine targeting LP.8.1—coordinating with European variant strategy recommendations.
🧬 Evaxion reports that 80 percent of targets in its Phase 2 cancer vaccine trial triggered tumor-specific responses—while actively seeking global R&D partners.
🏭 SK Bioscience expands its L HOUSE facility in Korea to support worldwide launch of GBP410, a 21-valent pneumococcal vaccine co-developed with Sanofi.
🦠 Moderna’s H5 avian flu vaccine delivers impressive Phase 1/2 results—achieving protective antibody levels in 97.8 percent of participants despite HHS funding denial.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine research
#VaccineResearch #Spikevax #OralVaccines #MenQuadfi #COVID19Updates #AvianFlu #Evaxion #CancerVaccines #SKBioscience #Pfizer #BioNTech #LucidQuest #PublicHealth #GlobalImmunization #BiotechNews #ClinicalTrials #HealthcareInnovation #PandemicPreparedness #mRNAVaccines #H5FluVaccine #LQVentures